adult glioblastoma
Information
- Disease name
- adult glioblastoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01165632 | Active, not recruiting | Early Phase 1 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | July 26, 2010 | December 30, 2024 |
| NCT02142803 | Active, not recruiting | Phase 1 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | May 20, 2014 | October 1, 2024 |
| NCT00268385 | Active, not recruiting | Phase 1 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | December 16, 2005 | April 24, 2025 |
| NCT02179086 | Active, not recruiting | Phase 2 | Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | October 27, 2014 | May 2026 |
| NCT00030498 | Completed | Phase 1 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | December 2001 | |
| NCT00039494 | Completed | Phase 2 | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | December 2002 | |
| NCT00045110 | Completed | Phase 1/Phase 2 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | August 2002 | December 2010 |
| NCT00045565 | Completed | Phase 1 | Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | October 2002 | |
| NCT00049387 | Completed | Phase 1 | Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | September 2002 | June 2007 |
| NCT00052208 | Completed | Phase 1/Phase 2 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | March 2002 | |
| NCT00058097 | Completed | Phase 2 | Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | August 2003 | |
| NCT00085254 | Completed | Phase 1/Phase 2 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | April 2005 | November 2012 |
| NCT00112736 | Completed | Phase 1/Phase 2 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | April 2005 | April 2014 |
| NCT00305656 | Completed | Phase 2 | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | January 2006 | |
| NCT00004262 | Completed | Phase 1 | Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme | November 1999 | |
| NCT00014170 | Completed | Phase 2 | Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | March 2001 | |
| NCT00016328 | Completed | Phase 2 | CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme | May 2001 | |
| NCT00731731 | Completed | Phase 1/Phase 2 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | July 10, 2009 | November 1, 2019 |
| NCT00823797 | Completed | Phase 2 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | October 2008 | April 2017 |
| NCT00902577 | Completed | Phase 2 | MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme | August 24, 2009 | January 31, 2018 |
| NCT00979862 | Completed | Phase 1 | Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma | March 2010 | February 2014 |
| NCT00980343 | Completed | Phase 2 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | February 2010 | June 2012 |
| NCT01051557 | Completed | Phase 1/Phase 2 | Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | January 27, 2010 | September 30, 2020 |
| NCT01062425 | Completed | Phase 2 | Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma | February 26, 2010 | May 20, 2022 |
| NCT01119599 | Completed | Phase 1 | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | May 2010 | |
| NCT01131234 | Completed | Phase 1 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | May 2010 | September 2014 |
| NCT01172964 | Completed | Phase 1 | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | August 2010 | February 11, 2015 |
| NCT01234740 | Completed | Phase 1 | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases | December 2010 | March 2013 |
| NCT01342757 | Completed | N/A | Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma | December 2010 | May 2012 |
| NCT01648348 | Completed | Phase 1/Phase 2 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | November 2012 | April 15, 2017 |
| NCT01730950 | Completed | Phase 2 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | December 20, 2012 | December 22, 2022 |
| NCT01753713 | Completed | Phase 2 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | December 20, 2012 | September 20, 2017 |
| NCT01806675 | Completed | Phase 1/Phase 2 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | March 4, 2013 | April 2019 |
| NCT01894061 | Completed | Phase 2 | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | June 12, 2013 | July 28, 2019 |
| NCT01977677 | Completed | Phase 1/Phase 2 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | November 2014 | September 2018 |
| NCT02015819 | Completed | Phase 1 | Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas | October 7, 2014 | October 7, 2017 |
| NCT02060890 | Completed | Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma | August 2014 | May 10, 2017 | |
| NCT02186509 | Completed | Phase 1 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | January 30, 2015 | December 31, 2018 |
| NCT02227901 | Completed | Phase 1 | Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | September 2002 | April 2014 |
| NCT02364206 | Completed | Phase 1/Phase 2 | Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma | June 8, 2015 | August 2019 |
| NCT04143425 | Completed | Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma | February 6, 2020 | November 1, 2022 | |
| NCT00238303 | Completed | Phase 2 | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | September 2005 | March 2010 |
| NCT00004146 | Completed | Phase 2 | Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM | March 2000 | January 2010 |
| NCT00305864 | Completed | Phase 1/Phase 2 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | February 9, 2006 | March 15, 2011 |
| NCT00316849 | Completed | Phase 1 | Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | May 2006 | |
| NCT00329719 | Completed | Phase 1/Phase 2 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | March 24, 2006 | February 2, 2013 |
| NCT00335764 | Completed | Phase 1/Phase 2 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | April 2006 | September 2012 |
| NCT00379080 | Completed | Phase 1/Phase 2 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | January 2007 | June 2013 |
| NCT00423735 | Completed | Phase 2 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | January 24, 2007 | September 4, 2018 |
| NCT00433381 | Completed | Phase 2 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | March 1, 2007 | February 16, 2011 |
| NCT00445588 | Completed | Phase 2 | Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | January 2007 | August 2009 |
| NCT00459381 | Completed | Phase 2 | Pazopanib in Treating Patients With Recurrent Glioblastoma | May 2007 | December 2008 |
| NCT00499473 | Completed | Phase 2 | Sunitinib in Treating Patients With Recurrent Malignant Gliomas | June 2007 | October 2014 |
| NCT00540722 | Completed | Phase 2 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | January 2008 | June 2012 |
| NCT00641706 | Completed | Phase 2 | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | July 2008 | November 2010 |
| NCT00650923 | Completed | Phase 1 | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma | July 2008 | December 2013 |
| NCT00662506 | Completed | Phase 1/Phase 2 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | April 2008 | April 2014 |
| NCT02613988 | Recruiting | N/A | Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas | January 12, 2020 | December 2025 |
| NCT04573140 | Recruiting | Phase 1 | A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) | October 26, 2021 | July 31, 2027 |
| NCT01103375 | Terminated | Phase 1 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma | May 2010 | March 2013 |
| NCT02967380 | Terminated | N/A | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases | December 14, 2011 | October 14, 2015 |
| NCT01122888 | Terminated | Phase 1 | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme | December 2009 | April 2015 |
| NCT01122901 | Terminated | Phase 2 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma | December 2010 | August 2015 |
| NCT01996527 | Terminated | Early Phase 1 | 3T MRI Biomarkers of Glioma Treatment Response | May 2012 | January 1, 2016 |
| NCT01148966 | Terminated | Phase 1 | Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors | June 2010 | |
| NCT00430079 | Terminated | N/A | Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma | July 2001 | |
| NCT00075491 | Terminated | Phase 2 | Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme | December 2003 | |
| NCT00005856 | Terminated | Phase 1/Phase 2 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | December 2000 | |
| NCT00110032 | Terminated | Phase 1 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors | June 2005 | |
| NCT02175745 | Terminated | N/A | 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas | December 2014 | December 2015 |
| NCT00112866 | Terminated | Phase 2 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme | January 2005 | March 2009 |
| NCT01189240 | Terminated | Phase 1/Phase 2 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | December 2010 | February 2015 |
| NCT01234805 | Terminated | N/A | Yoga Therapy in Treating Patients With Malignant Brain Tumors | December 2010 | September 2012 |
| NCT01269411 | Terminated | Phase 1 | RO4929097 in Treating Patients With Recurrent Invasive Gliomas | July 2011 | |
| NCT02530502 | Terminated | Phase 1 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | September 30, 2015 | February 12, 2020 |
| NCT01378481 | Terminated | Phase 1 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | June 2012 | August 2013 |
| NCT01478321 | Terminated | Phase 2 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | December 14, 2011 | September 12, 2018 |
| NCT01575275 | Terminated | Phase 2 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme | May 2012 | August 2014 |
| NCT00006773 | Terminated | Phase 1 | Bortezomib in Treating Patients With Recurrent Glioma | May 2001 | |
| NCT02194452 | Withdrawn | N/A | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors | September 2013 | March 2017 |
| NCT02055196 | Withdrawn | Phase 1 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas |